Grundläggande statistik
| LEI | 529900R7DZDU655YTV33 |
| CIK | 1641640 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Nabriva Therapeutics plc
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| October 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37558 Nabriva Therapeutics plc (Exact name of registrant as specified in |
|
| October 20, 2023 |
As filed with the Securities and Exchange Commission on October 19, 2023 As filed with the Securities and Exchange Commission on October 19, 2023 Registration No. |
|
| October 20, 2023 |
As filed with the Securities and Exchange Commission on October 19, 2023 As filed with the Securities and Exchange Commission on October 19, 2023 Registration No. |
|
| October 20, 2023 |
As filed with the Securities and Exchange Commission on October 19, 2023 As filed with the Securities and Exchange Commission on October 19, 2023 Registration No. |
|
| October 20, 2023 |
As filed with the Securities and Exchange Commission on October 19, 2023 As filed with the Securities and Exchange Commission on October 19, 2023 Registration No. |
|
| October 20, 2023 |
As filed with the Securities and Exchange Commission on October 19, 2023 As filed with the Securities and Exchange Commission on October 19, 2023 Registration No. |
|
| October 20, 2023 |
As filed with the Securities and Exchange Commission on October 19, 2023 As filed with the Securities and Exchange Commission on October 19, 2023 Registration No. |
|
| October 20, 2023 |
As filed with the Securities and Exchange Commission on October 19, 2023 As filed with the Securities and Exchange Commission on October 19, 2023 Registration No. |
|
| October 20, 2023 |
As filed with the Securities and Exchange Commission on October 19, 2023 As filed with the Securities and Exchange Commission on October 19, 2023 Registration No. |
|
| October 20, 2023 |
As filed with the Securities and Exchange Commission on October 19, 2023 As filed with the Securities and Exchange Commission on October 19, 2023 Registration No. |
|
| October 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 14, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File No. 001-37558 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: June 30, 2023 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q For the Tr |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2023 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| July 31, 2023 |
Exhibit 2.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. WARNING: THE TAKING OF THIS DOCUMENT OR ANY CERTIFIED COPY THEREOF OR ANY OTHER DOCUMENT WHICH CONSTITUTES SUBSTITUTE DOCUMENTATION OF THIS DOCUMENT, INCLUDING |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2023 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| July 7, 2023 |
Consulting Agreement, by and between Nabriva Therapeutics US, Inc. and J. Christopher Naftzger Exhibit 10.4 NABRIVA THERAPEUTICS US, INC. CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is effective as of July 8, 2023 (the “Effective Date”) by and between Nabriva Therapeutics US, Inc., a Delaware corporation, with a business address of 414 Commerce Drive, Suite 120, Fort Washington PA 19304 (“Company”), and J. Christopher Naftzger having an address at [**] (“Consultant”). WHERE |
|
| July 7, 2023 |
Exhibit 10.1 SEPARATION AND RELEASE OF CLAIMS AGREEMENT This Separation and Release of Claims Agreement (the “Agreement”) is made as of the Agreement Effective Date (as defined below) between Nabriva Therapeutics US, Inc. (the “Company”) and Daniel Dolan (the “Executive”) (together, the “Parties”). RECITALS WHEREAS, the Company and Executive are parties to the Employment Agreement dated as of Marc |
|
| July 7, 2023 |
Consulting Agreement, by and between Nabriva Therapeutics US, Inc. and Daniel Dolan Exhibit 10.3 NABRIVA THERAPEUTICS US, INC. CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is effective as of July 1, 2023 (the “Effective Date”) by and between Nabriva Therapeutics US, Inc., a Delaware corporation, with a business address of 414 Commerce Drive, Suite 120, Fort Washington PA 19304 (“Company”), and Daniel Dolan having an address at [**] (“Consultant”). WHEREAS, Company |
|
| July 7, 2023 |
Exhibit 10.2 SEPARATION AND RELEASE OF CLAIMS AGREEMENT This Separation and Release of Claims Agreement (the “Agreement”) is made as of the Agreement Effective Date (as defined below) between Nabriva Therapeutics US, Inc. (the “Company”) and J. Christopher Naftzger (the “Executive”) (together, the “Parties”). RECITALS WHEREAS, the Company and Executive are parties to the Employment Agreement dated |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 25, 2023 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commission |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 15, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File No. 001-37558 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the T |
|
| April 17, 2023 |
Exhibit 10.60 SEPARATION AND RELEASE OF CLAIMS AGREEMENT This SEPARATION AND RELEASE OF CLAIMS AGREEMENT (the “Agreement”) is made as of the Agreement Effective Date (as defined below) between Nabriva Therapeutics US, Inc. (the “Company”) and Christine Guico-Pabia (“Executive”) (together, the “Parties”). RECITALS WHEREAS, the Company and Executive are parties to the Employment Agreement dated as o |
|
| April 17, 2023 |
Consulting Agreement, by and between Nabriva Therapeutics US, Inc. and Christine Guico-Pabia Exhibit 10.61 NABRIVA THERAPEUTICS US, INC. CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is effective as of February 1, 2023 (the “Effective Date”) by and between Nabriva Therapeutics US, Inc., a Delaware corporation, with a business address of 414 Commerce Drive, Suite 120, Fort Washington PA 19304 (“Company”), and Christine Guico-Pabia having an address at [**] (“Consultant”). WH |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-375 |
|
| April 17, 2023 |
Subsidiaries of Nabriva Therapeutics plc Exhibit 21.1 SUBSIDIARIES OF NABRIVA THERAPEUTICS plc Nabriva Therapeutics GmbH Austria Nabriva Therapeutics Ireland Designated Activity Company Ireland Zavante Therapeutics, Inc. Delaware Nabriva Therapeutics US, Inc. Delaware |
|
| April 17, 2023 |
Exhibit 10.62 THIRD AMENDMENT to API SUPPLY AGREEMENT THIS THIRD AMENDMENT (“Amendment”) is entered into by and between Nabriva Therapeutics Ireland DAC, with a principal place of business at Alexandra House, Office 225/227, The Sweepstakes, Ballsbridge, Dublin 4, D04 C7H2, Ireland (“Nabriva”), and Hovione Limited, (“Hovione”). All capitalized terms not defined in this Amendment shall have the sam |
|
| March 31, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File No. 001-37558 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ¨Form 20-F ¨ Form 11-K ¨ Form10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: December 31, 2022 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q For the |
|
| February 6, 2023 |
Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. January 31, 2023 Nabriva Therapeutics Ireland DAC Alexandra House, Office 225/227, The Sweepstakes, Ballsbridge, Dublin 4, D04 C7H2, Ireland Attn: Dan Dolan, D |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2023 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| January 20, 2023 |
Consulting Agreement, by and between Nabriva Therapeutics US, Inc. and Steven Gelone Exhibit 10.4 NABRIVA THERAPEUTICS US, INC. CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is effective as of January 16, 2023 (the “Effective Date”) by and between Nabriva Therapeutics US, Inc., a Delaware corporation, with a business address of 414 Commerce Drive, Suite 120, Fort Washington PA 19304 (“Company”), and Steven P. Gelone having an address at [**] (“Consultant”). WHEREAS, |
|
| January 20, 2023 |
Consulting Agreement, by and between Nabriva Therapeutics US, Inc. and Theodore Schroeder Exhibit 10.3 NABRIVA THERAPEUTICS US, INC. CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is effective as of January 16, 2023 (the “Effective Date”) by and between Nabriva Therapeutics US, Inc., a Delaware corporation, with a business address of 414 Commerce Drive, Suite 120, Fort Washington PA 19304 (“Company”), and Theodore R. Schroeder having an address at [**] (“Consultant”). WHE |
|
| January 20, 2023 |
Exhibit 10.2 SEPARATION AND RELEASE OF CLAIMS AGREEMENT This Separation and Release of Claims Agreement (the “Agreement”) is made as of the Agreement Effective Date (as defined below) between Nabriva Therapeutics US, Inc. (the “Company”) and Steven Gelone (“Executive”) (together, the “Parties”). RECITALS WHEREAS, the Company and Executive are parties to the Third Amended and Restated Employment Ag |
|
| January 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2023 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| January 20, 2023 |
Exhibit 10.1 SEPARATION AND RELEASE OF CLAIMS AGREEMENT This Separation and Release of Claims Agreement (the “Agreement”) is made as of the Agreement Effective Date (as defined below) between Nabriva Therapeutics US, Inc. (the “Company”) and Theodore R. Schroeder (“Executive”) (together, the “Parties”). RECITALS WHEREAS, the Company and Executive are parties to the Amended and Restated Employment |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2023 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| January 9, 2023 |
Press release issued by Nabriva Therapeutics plc, dated January 6, 2023 Exhibit 3.1 Nabriva Therapeutics Provides Corporate Update -Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations- -Company To Continue Work With Torreya Capital On Asset Monetization- DUBLIN, Ireland, Jan. 06, 2023 (GLOBE NEWSWIRE) - Nabriva Therapeutics plc (NASDAQ: NBRV) today announced that, after an assessment of strategic options, its Board of Directors approved a plan |
|
| November 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 28, 2022 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 10, 2022 |
Exhibit 99.1 Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update -Shifted Focus to SIVEXTRO to Enable Cost Cutting- -Cash Runway Extended into Q1 2023- -Q3 2022 Total Revenue of $9.2 Million- -Engaged Torreya Capital As Strategic Advisor- -Conference call today at 4:30 p.m. Eastern Time- Dublin Ireland, November 10, 2022 – Nabriva The |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 10, 2022 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| October 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 30, 2022 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Comm |
|
| September 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 15, 2022 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Comm |
|
| September 16, 2022 |
Amended and Restated Memorandum and Articles of Association of Nabriva Therapeutics plc Exhibit 3.1 COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES CONSTITUTION OF NABRIVA THERAPEUTICS PUBLIC LIMITED COMPANY (adopted on 23 June 2017 and amended on 2 December 2020, 28 July 2021, and 15 September 2022) COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF NABRIVA THERAPEUTICS PUBLIC LIMITED COMPANY 1. The name of the Company is Nabriva Therapeutics pu |
|
| August 17, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 11, 2022 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commiss |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 11, 2022 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commiss |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 3, 2022 |
Exhibit 99.1 ? Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update ? -Net Product Sales of $8.7M Grew 25% versus Q2 2021- ? -SIVEXTRO Prescription Demand Grew 28% versus Q2 2021- ? -Conference Call Today at 4:30 p.m. Eastern Time- ? Dublin Ireland, August 3, 2022 ? Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the com |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of Earliest Event Reported): August 3, 2022 ? NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) ? ? ? ? Ireland 001-37558 Not Applicable (State or other jurisdiction of inco |
|
| August 3, 2022 |
Exhibit 10.1 ? Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. ? THIRD AMENDMENT TO SALES PROMOTION AND DISTRIBUTION AGREEMENT ? THIRD AMENDMENT TO SALES PROMOTION AND DISTRIBUTION AGREEMENT dated as of the effective dat |
|
| July 11, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| July 6, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2022 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commissio |
|
| June 29, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of Earliest Event Reported): May 5, 2022 ? NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) ? ? ? ? Ireland 001-37558 Not Applicable (State or other jurisdiction of incorpo |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 5, 2022 |
Exhibit 99.1 ? Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update ? -SIVEXTRO Distribution and Promotion Agreement with Merck Formally Extended Through at Least 2026- ? -SIVEXTRO Prescription Demand Grew 10% Versus Q1 2021- ? -Phase 1 XENLETA Cystic Fibrosis Trial Enrollment Progressing- ? -Conference Call Today at 4:30 p.m. Eastern Time- ? Dublin Ire |
|
| March 29, 2022 |
Exhibit 99.1 ? Nabriva Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update ? -Total revenue of $9.3 million driven by continued SIVEXTRO prescription growth- ? -Net product sales increased 8% sequentially in Q4 2021 versus Q3 2021- ? -Cash runway extended well into Q4 2022- ? -Conference call today at 4:30 p.m. Eastern Time- ? Dublin Ireland, Ma |
|
| March 29, 2022 |
Subsidiaries of Nabriva Therapeutics plc Exhibit 21.1 ? SUBSIDIARIES OF NABRIVA THERAPEUTICS plc ? Nabriva Therapeutics GmbH Austria Nabriva Therapeutics Ireland Designated Activity Company Ireland Zavante Therapeutics, Inc. Delaware Nabriva Therapeutics US, Inc. Delaware ? |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 29, 2022 |
Form of Contingent RSU Award Agreement under the 2020 Share Incentive Plan, as amended Exhibit 10.57 NABRIVA THERAPEUTICS PLC Restricted Share Unit Agreement Granted Under 2020 Share Incentive Plan ? This Restricted Share Unit Agreement (this ?Agreement?) is made between Nabriva Therapeutics plc, a public limited company organized under the laws of Ireland (the ?Company?), and the Participant pursuant to the 2020 Share Incentive Plan (as amended from time to time, the ?Plan?). ? Not |
|
| March 29, 2022 |
Up to $10,709,591 Ordinary Shares 424B5 1 tm2210732d1424b5.htm 424B5 Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-248530 PROSPECTUS SUPPLEMENT (TO PROSPECTUS SUPPLEMENT DATED MAY 6, 2021 TO PROSPECTUS DATED SEPTEMBER 11, 2020) Up to $10,709,591 Ordinary Shares This prospectus supplement amends and supplements the information in the prospectus, dated September 11, 2020, filed with the Securities and Exchange Com |
|
| March 29, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of Earliest Event Reported): March 29, 2022 ? NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) ? ? ? ? Ireland 001-37558 Not Applicable (State or other jurisdiction of inco |
|
| March 29, 2022 |
Exhibit 10.58 ? Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. SIDE AGREEMENT to the Manufacturing Services Agreement effective as of May 08th, 2017 This Side Agreement (the ?Side Agreement?) to the above-mentioned Manu |
|
| March 24, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 24, 2022 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commiss |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| February 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 28, 2022 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| January 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 18, 2022 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| January 18, 2022 |
DEFA14A 1 tm222155d6defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (a |
|
| January 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| January 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| January 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 14, 2022 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| January 10, 2022 |
Exhibit 99.1 Nabriva Therapeutics Provides Business Update and Announces Preliminary Financial Results for the Fourth Quarter of 2021 -SIVEXTRO? (tedizolid phosphate) remains on track for return to historical peak sales by mid-2022- -XENLETA? (lefamulin) Phase I Cystic Fibrosis (CF) trial on track to enroll first patient in Q122- -Cash resources of $47.7 million as of 12/31/21 provides cash runway |
|
| January 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 10, 2022 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| January 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| January 7, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 4, 2022 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commiss |
|
| December 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| December 22, 2021 |
DEFA14A 1 tm2136103d1defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only ( |
|
| December 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 22, 2021 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| November 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| November 19, 2021 |
NBRV / Nabriva Therapeutics AG / Lincoln Park Capital Fund, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NABRIVA THERAPEUTICS PLC (Name of Issuer) ORDINARY SHARES, $0.01 NOMINAL VALUE (Title of Class of Securities) G63637113 (CUSIP Number) November 12, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| November 19, 2021 |
EXHIBIT 1 Joint Filing Agreement The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| November 9, 2021 |
Exhibit 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?), is made as of August 23, 2021 by and between Nabriva Therapeutics US, Inc. (the ?Company?), and Christine Guico-Pabia (the ?Executive?) (together, the ?Parties?). RECITALS ? WHEREAS, the Company desires employ the Executive as its Chief Medical Officer and as Chief Medical Officer of its group of companies: and ? WHEREA |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 9, 2021 |
As filed with the Securities and Exchange Commission on November 9, 2021 As filed with the Securities and Exchange Commission on November 9, 2021 Registration No. |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of Earliest Event Reported): November 9, 2021 ? NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) ? ? ? ? Ireland 001-37558 Not Applicable (State or other jurisdiction of in |
|
| November 9, 2021 |
Exhibit 99.1 ? Nabriva Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update ? -Revenues of $8.9 million increased 8% sequentially versus Q2 2021- ? -SIVEXTRO Net Sales & Prescriptions both grew 14% sequentially versus Q2 2021- ? -Cash runway extended to substantially through Q2 2022- ? -Conference call today at 4:30 p.m. Eastern Time- ? Dublin Ireland, November |
|
| November 9, 2021 |
Exhibit 10.1 ? EMPLOYMENT AGREEMENT ? THIS EMPLOYMENT AGREEMENT (the ?Agreement?), is made as of August 24, 2021 by and between Nabriva Therapeutics US, Inc. (the ?Company?), and J. Christopher Naftzger (the ?Executive?) (together, the ?Parties?). ? RECITALS ? WHEREAS, the Company desires employ the Executive as its General Counsel and as General Counsel of its group of companies: and ? WHEREAS, t |
|
| November 1, 2021 |
Nabriva Therapeutics plc 17,632,474 Ordinary Shares TABLE OF CONTENTS ?Filed Pursuant to Rule 424B3? ?Registration No. 333-260146? PROSPECTUS Nabriva Therapeutics plc 17,632,474 Ordinary Shares ? This prospectus relates to the resale, from time to time, of up to 17,632,474 of our ordinary shares, nominal value $0.01 per share, by the selling shareholder, Lincoln Park Capital Fund, LLC, which we refer to as Lincoln Park or the selling shareholder. T |
|
| October 28, 2021 |
NABRIVA THERAPEUTICS PLC 25-28 North Wall Quay, IFSC Dublin 1, Ireland NABRIVA THERAPEUTICS PLC 25-28 North Wall Quay, IFSC Dublin 1, Ireland October 28, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| October 8, 2021 |
2021 Inducement Share Incentive Plan, as amended Exhibit 10.43 NABRIVA THERAPEUTICS plc 2021 INDUCEMENT SHARE INCENTIVE PLAN 1. Purpose The purpose of this 2021 Inducement Share Incentive Plan (the ?Plan?) of Nabriva Therapeutics plc, a public limited company organized under the laws of the Republic of Ireland (the ?Company?), is to advance the interests of the Company?s shareholders by enhancing the Company?s ability to attract, retain and moti |
|
| October 8, 2021 |
As filed with Securities and Exchange Commission on October 8, 2021 TABLE OF CONTENTS As filed with Securities and Exchange Commission on October 8, 2021 Registration No. |
|
| September 27, 2021 |
Exhibit 10.1 EXECUTION COPY PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the ?Agreement?), dated as of September 24, 2021 (the ?Execution Date?), is made by and between NABRIVA THERAPEUTICS PLC., an Irish incorporated public limited company (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the ?Investor?). Capitalized terms used herein and not otherwise def |
|
| September 27, 2021 |
Exhibit 4.1 Execution Copy REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of September 24, 2021, is made by and between NABRIVA THERAPEUTICS PLC, an Irish incorporated public limited company (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the ?Buyer?). Capitalized terms u |
|
| September 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 24, 2021 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Comm |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 5, 2021 |
Exhibit 10.1 ? Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. ? FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?), dated as of June 2, 2021 (the ?Fou |
|
| August 5, 2021 |
Exhibit 10.4 ? Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. ? SECOND AMENDMENT TO SALES PROMOTION AND DISTRIBUTION AGREEMENT THIS SECOND AMENDMENT, dated as of the effective date set forth in Section 2.01 below (this |
|
| August 5, 2021 |
Exhibit 10.5 ? Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. ? FIRST AMENDMENT to API SUPPLY AGREEMENT ? THIS FIRST AMENDMENT (?Amendment?) is entered into by and between Nabriva Therapeutics Ireland DAC, with a princi |
|
| August 5, 2021 |
Amended and Restated Memorandum and Articles of Association of Nabriva Therapeutics plc Exhibit 3.1 ? ? ? ? ? ? ? ? ? ? ? ? ? ? COMPANIES ACT 2014 ? ? ? ? A PUBLIC COMPANY LIMITED BY SHARES ? ? ? ? ? ? ? ? ? ? ? CONSTITUTION ? OF ? NABRIVA THERAPEUTICS PUBLIC LIMITED COMPANY ? (adopted on 23 June 2017 and amended on 2 December 2020 and 28 July 2021) ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 1 Exhibit 3.1 ? ? COMPANIES ACT 2014 ? A PUBLIC COMPANY LIMITED BY SHARES ? ? ? MEMORANDUM OF ASSO |
|
| August 5, 2021 |
Exhibit 10.3 ? Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. ? FIRST AMENDMENT TO SALES PROMOTION AND DISTRIBUTION AGREEMENT FIRST AMENDMENT TO SALES PROMOTION AND DISTRIBUTION AGREEMENT, dated as of the effective date |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of Earliest Event Reported): August 5, 2021 ? NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) ? ? ? ? Ireland 001-37558 Not Applicable (State or other jurisdiction of inco |
|
| August 5, 2021 |
Exhibit 10.2 Execution version confidential ASSIGNMENT, ASSUMPTION AND NOVATION AGREEMENT This ASSIGNMENT, ASSUMPTION AND NOVATION AGREEMENT (this ?Agreement?), dated as of May 13, 2021 (the ?Effective Date?), is by and among Roivant Sciences Ltd. (?Roivant?), Roivant China Holdings Ltd. (?Roivant China?), Sinovant Sciences HK Limited (?Sinovant HK?), Sinovant Sciences Co., Ltd. (?Sinovant,? and t |
|
| August 5, 2021 |
Exhibit 99.1 Nabriva Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update -Revenues of $8.2 million driven by launch of own National Drug Code (NDC) for SIVEXTRO- -Cash runway substantially through Q1 2022- -Announced positive Phase 3 trial results for lefamulin in China, commercial rights assigned to Sumitomo Pharmaceuticals (Suzhou) Co., Ltd (SPC)- -Conferen |
|
| July 30, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 28, 2021 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| July 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| July 1, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??????) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by |
|
| June 18, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??????) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by |
|
| June 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 1, 2021 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commission |
|
| May 25, 2021 |
Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 25, 2021 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commission |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of Earliest Event Reported): May 6, 2021 ? NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) ? ? ? ? Ireland 001-37558 Not Applicable (State or other jurisdiction of incorpo |
|
| May 6, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 6, 2021 |
Exhibit 10.1 NABRIVA THERAPEUTICS US, INC. CONSULTING AGREEMENT This Consulting Agreement (?Agreement?) is dated as of May 3, 2021 and effective as of May 3, 2021 (the ?Effective Date?) by and between Nabriva Therapeutics US, Inc., a Delaware corporation, with a business address of 414 Commerce Drive, Suite 120, Fort Washington, PA 19034 (?Company?), and Jennifer Schranz having an address at [**] |
|
| May 6, 2021 |
Exhibit 10.2 EXECUTION VERSION OPEN MARKET SALE AGREEMENTSM May 6, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Nabriva Therapeutics plc, an Irish incorporated public limited company (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Ag |
|
| May 6, 2021 |
Up to $50,000,000 Ordinary Shares TABLE OF CONTENTS ? Filed pursuant to Rule 424(b)(5)? ?Registration Statement No. 333-248530? PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED SEPTEMBER 11, 2020 ) Up to $50,000,000 Ordinary Shares ? We entered into an Open Market Sale AgreementSM, or the Sale Agreement, with Jefferies LLC, or Jefferies, on May 6, 2021, relating to the sale of our ordinary shares, nominal value $0.01 per share. In accor |
|
| May 6, 2021 |
Form of Share Option Agreement under the 2021 Inducement Share Incentive Plan ? Exhibit 10.6 NABRIVA THERAPEUTICS PLC NONSTATUTORY SHARE OPTION AGREEMENT GRANTED UNDER 2021 INDUCEMENT SHARE INCENTIVE PLAN ? This Nonstatutory Share Option Agreement (this ?Agreement?) is made between Nabriva Therapeutics plc, a public limited company organized under the laws of Ireland (the ?Company?), and the Participant pursuant to the 2021 Inducement Share Incentive Plan (the ?Plan?). NOTI |
|
| May 6, 2021 |
Form of Share Option Agreement under the 2020 Share Incentive Plan, as amended ? Exhibit 10.3 NABRIVA THERAPEUTICS PLC SHARE OPTION AGREEMENT GRANTED UNDER 2020 SHARE INCENTIVE PLAN This Share Option Agreement (this ?Agreement?) is made between Nabriva Therapeutics plc, a public limited company organized under the laws of Ireland (the ?Company?), and the Participant pursuant to the 2020 Share Incentive Plan (as amended from time to time, the ?Plan?). NOTICE OF GRANT I. Parti |
|
| May 6, 2021 |
? Exhibit 10.4 Restricted Share Unit Agreement Granted Under 2020 Share Incentive Plan ? This Restricted Share Unit Agreement (this ?Agreement?) is made between Nabriva Therapeutics plc, a public limited company organized under the laws of Ireland (the ?Company?), and the Participant pursuant to the 2020 Share Incentive Plan (as amended from time to time, the ?Plan?). ? Notice of Grant ? I.Partici |
|
| May 6, 2021 |
? Exhibit 10.5 NABRIVA THERAPEUTICS PLC Restricted Share Unit Agreement Granted Under 2020 Share Incentive Plan ? This Restricted Share Unit Agreement (this ?Agreement?) is made between Nabriva Therapeutics plc, a public limited company organized under the laws of Ireland (the ?Company?), and the Participant pursuant to the 2020 Share Incentive Plan (as amended from time to time, the ?Plan?). ? No |
|
| May 6, 2021 |
Exhibit 99.1 Nabriva Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates -First quarter of full complement of 60 sales representatives further expanding the reach of XENLETA® (lefamulin) and SIVEXTRO® (tedizolid phosphate) in the community- -Commenced exclusive distribution of SIVEXTRO in the U.S. on April 12, 2021 and moving forward will record 100% of net pro |
|
| April 15, 2021 |
Exhibit 99.1 UNIQUELY POSITIONED TO DELIVER INNOVATIVE TREATMENTS FOR PATIENTS WITH INFECTIOUS DISEASES April 2021 Safe Harbor and Disclaimer Any statements in this presentation about future expectations, plans and prospects for Nabriva Therapeutics, including but not limited to statements about its ability to successfully commercialize XENLETA for the treatment of CABP, including the availability |
|
| April 15, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 15, 2021 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| March 11, 2021 |
? Exhibit 10.18 ? AMENDED AND RESTATED EMPLOYMENT AGREEMENT ? THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?), is made as of March 10, 2021 by and between Nabriva Therapeutics US, Inc. (the ?Company?), and Theodore R. Schroeder (the ?Executive?) (together, the ?Parties?). ? RECITALS ? WHEREAS, the Company and the Executive are parties to that certain Employment Agreement effective |
|
| March 11, 2021 |
Exhibit 10.31 ? THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENT ? THIS THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?), is made as of March 10, 2021 by and between Nabriva Therapeutics US, Inc. (the ?Company?), and Steven Gelone (the ?Executive?) (together, the ?Parties?). ? RECITALS ? WHEREAS, the Company and the Executive are parties to that certain Second Amended and Restated |
|
| March 11, 2021 |
2021 Inducement Share Incentive Plan ? Exhibit 10.46 NABRIVA THERAPEUTICS plc 2021 INDUCEMENT SHARE INCENTIVE PLAN 1. Purpose The purpose of this 2021 Inducement Share Incentive Plan (the ?Plan?) of Nabriva Therapeutics plc, a public limited company organized under the laws of the Republic of Ireland (the ?Company?), is to advance the interests of the Company?s shareholders by enhancing the Company?s ability to attract, retain and mo |
|
| March 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of Earliest Event Reported): March 11, 2021 ? NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) ? ? ? ? Ireland 001-37558 Not Applicable (State or other jurisdiction of inco |
|
| March 11, 2021 |
? Exhibit 10.48 ? Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. ? AMENDMENT TO THE LICENSE AGREEMENT This Amendment to the License Agreement (this Amendment) is made and entered into effective as of October 29, 2020 (the Effe |
|
| March 11, 2021 |
Description of the Registrant’s Securities Registered under Section 12 of the Exchange Act Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of registered securities of Nabriva Therapeutics plc (?us,? ?our,? ?we? or the ?Company?) is intended as a summary only and therefore is not a complete description. This description is based upon, and is qualified by reference to, our memorandum and articles of association and applicable |
|
| March 11, 2021 |
2021 Inducement Share Incentive Plan EX-99.1 4 tm219117d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 NABRIVA THERAPEUTICS plc 2021 INDUCEMENT SHARE INCENTIVE PLAN 1. Purpose The purpose of this 2021 Inducement Share Incentive Plan (the “Plan”) of Nabriva Therapeutics plc, a public limited company organized under the laws of the Republic of Ireland (the “Company”), is to advance the interests of the Company’s shareholders by enhancing the Co |
|
| March 11, 2021 |
As filed with the Securities and Exchange Commission on March 11, 2021 Registration No. |
|
| March 11, 2021 |
Subsidiaries of Nabriva Therapeutics plc Exhibit 21.1 ? SUBSIDIARIES OF NABRIVA THERAPEUTICS plc ? Nabriva Therapeutics GmbH Austria Nabriva Therapeutics Ireland Designated Activity Company Ireland Zavante Therapeutics, Inc. Delaware Nabriva Therapeutics US, Inc. Delaware ? |
|
| March 11, 2021 |
Exhibit 10.49 ? ? NABRIVA THERAPEUTICS US, INC. CONSULTING AGREEMENT This Consulting Agreement (?Agreement?) is dated as of March 9, 2021 and effective as of March 15, 2021 (the ?Effective Date?) by and between Nabriva Therapeutics US, Inc., a Delaware corporation, with a business address of 1000 Continental Drive, Suite 600, King of Prussia, Pennsylvania 19406 (?Company?), and Sender Consulting L |
|
| March 11, 2021 |
Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 11, 2021 |
Exhibit 99.1 Nabriva Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Updates -Relaunched XENLETA® (lefamulin) and SIVEXTRO® (tedizolid phosphate) in the community with 60 sales representatives- -Nabriva plans to initiate a Phase 1 clinical trial of XENLETA in patients with cystic fibrosis- -Conference call today at 4:30 p.m. Eastern Time- Dublin Irela |
|
| March 11, 2021 |
? Exhibit 10.47 ? EMPLOYMENT AGREEMENT ? THIS EMPLOYMENT AGREEMENT (the ?Agreement?), is made as of March 10, 2021 by and between Nabriva Therapeutics US, Inc. (the ?Company?), and Daniel Dolan (the ?Executive?) (together, the ?Parties?). ? RECITALS ? WHEREAS, the Company desires to employ the Executive as its Chief Financial Officer and as Chief Financial Officer of its group of companies; and ? |
|
| March 11, 2021 |
? Exhibit 10.8 ? AMENDED AND RESTATED EMPLOYMENT AGREEMENT ? THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?), is made as of March 10, 2021 by and between Nabriva Therapeutics US, Inc. (the ?Company?), and Robert Crotty (the ?Executive?) (together, the ?Parties?). ? RECITALS ? WHEREAS, the Company and the Executive are parties to that certain Employment Agreement effective as of Ju |
|
| March 1, 2021 |
Exhibit 99.1 Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules DUBLIN, Ireland and KING OF PRUSSIA, Pa., March 1, 2021 — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entere |
|
| March 1, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 1, 2021 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commissio |
|
| March 1, 2021 |
Exhibit 4.1 EXHIBIT C-1 ORDINARY SHARE PURCHASE WARRANT Nabriva Therapeutics plc Warrant Shares: Initial Exercise Date: March , 2021 Issue Date: March , 2021 THIS ORDINARY SHARE PURCHASE WARRANT (the ?Warrant?) certifies that, for value of $0.0001 received by the Company, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereina |
|
| March 1, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of March 1, 2021, between Nabriva Therapeutics plc, an Irish incorporated public limited company (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to th |
|
| March 1, 2021 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-248530 Prospectus Supplement (To Prospectus dated September 11, 2020) 9,761,010 Ordinary Shares Pre-Funded Warrants to Purchase up to 600,000 Ordinary Shares Warrants to Purchase up to 5,180,505 Ordinary Shares We are offering (1) 9,761,010 ordinary shares and accompanying warrants to purchase up to 4,880,505 ordin |
|
| March 1, 2021 |
Exhibit 4.2 EXHIBIT C-2 ORDINARY SHARE PRE-FUNDED PURCHASE WARRANT Nabriva Therapeutics plc Warrant Shares: Initial Exercise Date: March , 2021 Issue Date: March , 2021 THIS ORDINARY SHARE PRE-FUNDED PURCHASE WARRANT (the ?Warrant?) certifies that, for value received by the Company, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditi |
|
| February 26, 2021 |
Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer Exhibit 99.1 Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 26, 2021 - Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the appointment of Daniel Dolan as Chief Financial Officer ( |
|
| February 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 24, 2021 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 8, 2021 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| February 12, 2021 |
Exhibit 10.1 SUBLEASE AGREEMENT THIS SUBLEASE AGREEMENT (the "Sublease") is made as of this 8th day of February, 2021, by and between PROFESSIONAL PAYROLL SOLUTIONS, LLC, a Pennsylvania limited liability company, having an address at 4 Loretta Lane, Plymouth Meeting PA 19462 ("Sublandlord"), and NABRIVA THERAPEUTICS US, Inc., a Delaware corporation having an address at 1000 Continental Drive, Suit |
|
| February 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 1, 2021 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| February 1, 2021 |
Nabriva Therapeutics Announces Retirement of its Chief Financial Officer Exhibit 99.1 Nabriva Therapeutics Announces Retirement of its Chief Financial Officer DUBLIN, Ireland and KING OF PRUSSIA, Pa., February 1, 2021 — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the retirement of Gary Sender as Chief Financial Offic |
|
| December 14, 2020 |
Nabriva Therapeutics Announces Proposed Public Offering EX-99.1 4 tm2038388d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Nabriva Therapeutics Announces Proposed Public Offering DUBLIN, Ireland and KING OF PRUSSIA, Pa., December 10, 2020 — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has commenced a p |
|
| December 14, 2020 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 10, 2020, between Nabriva Therapeutics plc, an Irish incorporated public limited company (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject t |
|
| December 14, 2020 |
Nabriva Therapeutics Announces Pricing of $15 Million Public Offering Exhibit 99.2 Nabriva Therapeutics Announces Pricing of $15 Million Public Offering DUBLIN, Ireland and KING OF PRUSSIA, Pa., December 10, 2020 — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the pricing of its public offering of 6,000,000 ordinary |
|
| December 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 10, 2020 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| December 11, 2020 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-248530 Prospectus Supplement (To Prospectus dated September 11, 2020) 6,000,000 Ordinary Shares We are offering 6,000,000 ordinary shares pursuant to this prospectus supplement and the accompanying prospectus. Each ordinary share will be issued and sold at a fixed public offering price of $2.50 per share. Our ordin |
|
| December 10, 2020 |
Subject to Completion, dated December 10, 2020 TABLE OF CONTENTS The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| December 7, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 7, 2020 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| December 7, 2020 |
Exhibit 99.1 Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China -Amended agreement encompasses enhanced manufacturing collaboration and regulatory support -Accelerates milestone payments to Nabriva, including fourth quarter 2020 payment of $1 million DUBLIN, Ireland, December 7, 2020 - Nabriva Therapeutics plc (N |
|
| December 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 2, 2020 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| December 3, 2020 |
Amended and Restated Memorandum and Articles of Association of Nabriva Therapeutics plc Exhibit 3.1 COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES CONSTITUTION OF NABRIVA THERAPEUTICS PUBLIC LIMITED COMPANY (adopted on 23 June 2017 and amended on 2 December 2020) COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF NABRIVA THERAPEUTICS PUBLIC LIMITED COMPANY 1. The name of the Company is Nabriva Therapeutics public limited company. 2. The Company |
|
| November 5, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 5, 2020 |
Exhibit 10.1 VIA EMAIL August 5, 2020 Jennifer Schranz Re: Retention Agreement Dear Jennifer: As we have discussed, Nabriva Therapeutics US, Inc. (the “Company”) recognizes and appreciates the contributions you have made to the Company during your employment and wants you to remain committed and focused on delivering your goals and objectives during this important time for the Company. As an incen |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 5, 2020 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| November 5, 2020 |
Exhibit Ex99.1 Nabriva Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Updates -Relaunch of Xenleta® and Sivextro® commenced in late September- - Type A Meeting with FDA for Contepo™ held on October 30th - -Conference call today at 4:30 p.m. Eastern Time- Dublin Ireland, November 5, 2020 – Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged |
|
| September 9, 2020 |
CORRESP 1 filename1.htm Nabriva Therapeutics plc 25-28 North Wall Quay, IFSC, Dublin 1, Ireland September 9, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Nabriva Therapeutics plc Registration Statement on Form S-3 File No. 333-248530 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated und |
|
| September 1, 2020 |
Exhibit 4.2 NABRIVA THERAPEUTICS PLC and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) In |
|
| September 1, 2020 |
Exhibit 4.4 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE |
|
| September 1, 2020 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 1, 2020 Registration No. |
|
| September 1, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 1, 2020 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| September 1, 2020 |
Exhibit 4.5 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| September 1, 2020 |
Form of Subordinated Indenture Exhibit 4.3 NABRIVA THERAPEUTICS PLC and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314 |
|
| September 1, 2020 |
Up to $31,959,197 Ordinary Shares Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-223739 Prospectus Supplement (To Prospectus Dated April 27, 2018) Up to $31,959,197 Ordinary Shares We entered into an Open Market Sale AgreementSM, or the Sale Agreement, with Jefferies LLC, or Jefferies, on June 25, 2019, relating to the sale of our ordinary shares, nominal value $0.01 per share, for aggregate gros |
|
| August 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 6, 2020 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| August 6, 2020 |
Exhibit Ex99.1 Nabriva Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates -SIVEXTRO® adds revenue generating product creating additional scale and synergies- -Relaunch of XENLETA® and SIVEXTRO planned with targeted in-person promotion- -Conference call today at 4:30 p.m. Eastern Time- Dublin Ireland, August 6, 2020 – Nabriva Therapeutics plc (NASDAQ: NBRV), a |
|
| August 6, 2020 |
Exhibit 10.2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. SALES PROMOTION AND DISTRIBUTION AGREEMENT BY AND AMONG MSD INTERNATIONAL GMBH MERCK SHARP & DOHME CORP. and NABRIVA THERAPEUTICS IRELAND DESIGNATED ACTIVITY COMPANY |
|
| July 30, 2020 |
As filed with the Securities and Exchange Commission on July 29, 2020 Registration No. |
|
| July 30, 2020 |
2020 Share Incentive Plan, as amended Exhibit 99.1 NABRIVA THERAPEUTICS plc 2020 SHARE INCENTIVE PLAN 1. Purpose The purpose of this 2020 Share Incentive Plan (the “Plan”) of Nabriva Therapeutics plc, a public limited company organized under the laws of the Republic of Ireland (the “Company”), is to advance the interests of the Company’s shareholders by enhancing the Company’s ability to attract, retain and motivate persons who are ex |
|
| July 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 29, 2020 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| July 30, 2020 |
NABRIVA THERAPEUTICS plc 2020 SHARE INCENTIVE PLAN Exhibit 99.1 NABRIVA THERAPEUTICS plc 2020 SHARE INCENTIVE PLAN 1. Purpose The purpose of this 2020 Share Incentive Plan (the “Plan”) of Nabriva Therapeutics plc, a public limited company organized under the laws of the Republic of Ireland (the “Company”), is to advance the interests of the Company’s shareholders by enhancing the Company’s ability to attract, retain and motivate persons who are ex |
|
| July 15, 2020 |
Exhibit 99.1 Nabriva Therapeutics Enters into Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. - Accretive transaction creates synergies and scale that strengthen Nabriva’s community-focused commercialization organization to optimize product uptake - Nabriva partners with Amplity Health to provide community-focused customer engagement and sales initiatives |
|
| July 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 15, 2020 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commissio |
|
| June 25, 2020 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 22, 2020 |
Exhibit 99.1 Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for CONTEPO™ (fosfomycin) for injection Agency Cited Travel Restrictions and Inability to Conduct Onsite Inspections to Resolve Observations at Manufacturing Partner Facilities DUBLIN, Ireland, June 19, 2020 - Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and |
|
| June 22, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 19, 2020 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commissio |
|
| June 12, 2020 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 1, 2020 |
41,445,373 Ordinary Shares Warrants to Purchase 41,445,373 Ordinary Shares Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No. |
|
| June 1, 2020 |
Exhibit 99.1 Nabriva Therapeutics Announces $38 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 29, 2020 — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered i |
|
| June 1, 2020 |
Exhibit 4.1 ORDINARY SHARE PURCHASE WARRANT Nabriva Therapeutics plc Warrant Shares: Initial Exercise Date: June , 2020 Issue Date: June , 2020 THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value of $0.0001 received by the Company, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth |
|
| June 1, 2020 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 29, 2020, between Nabriva Therapeutics plc, an Irish incorporated public limited company (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the |
|
| June 1, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 29, 2020 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commission |
|
| June 1, 2020 |
Subject to completion, dated May 29, 2020 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No. |
|
| May 29, 2020 |
Exhibit 99.1 Nabriva Therapeutics Receives Positive EU CHMP Opinion for XENLETA™ (lefamulin) for the Treatment of Community Acquired Pneumonia (CAP) – If approved, XENLETA has the potential to be a first-in-class pleuromutilin antibiotic for the intravenous (IV) and oral treatment of adult patients with CAP in Europe – CHMP opinion supported by robust safety and efficacy data from two global pivot |
|
| May 29, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 29, 2020 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commission |
|
| May 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 26, 2020 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commission |
|
| May 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 11, 2020 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commission |
|
| May 11, 2020 |
EX-99.1 2 tm2019110d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Nabriva Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Updates -Cash runway extended into the fourth quarter of 2020 through judicious resource management- -XENLETA managed care coverage and patient reimbursement continues to strengthen- -Potential value-creating life cycle management for XENLETA initiated |
|
| May 11, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 1, 2020 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 29, 2020 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| April 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 7, 2020 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commissio |
|
| March 12, 2020 |
Exhibit 10.43 NABRIVA THERAPEUTICS PLC SHARE OPTION / CASH-SETTLED SHARE APPRECIATION RIGHT AGREEMENT GRANTED UNDER 2020 SHARE INCENTIVE PLAN This Share Option /Cash-Settled Share Appreciation Right Agreement (this “Agreement”) is made between Nabriva Therapeutics plc, a public limited company organized under the laws of Ireland (the “Company”), and the Participant pursuant to the 2020 Share Incen |
|
| March 12, 2020 |
Exhibit 10.42 NABRIVA THERAPEUTICS plc 2020 SHARE INCENTIVE PLAN 1. Purpose The purpose of this 2020 Share Incentive Plan (the “Plan”) of Nabriva Therapeutics plc, a public limited company organized under the laws of the Republic of Ireland (the “Company”), is to advance the interests of the Company’s shareholders by enhancing the Company’s ability to attract, retain and motivate persons who are e |
|
| March 12, 2020 |
Exhibit 99.1 Nabriva Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results and Recent Corporate Highlights -Prioritizing community opportunity for oral XENLETA given broad reimbursement coverage- -Reducing balance sheet risk through early paydown of a substantial portion of Hercules loan – -Pursuing options to provide lefamulin to patients with coronavirus with secondary bacteria |
|
| March 12, 2020 |
Exhibit 10.41 Execution Version THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of March 11, 2020 (the “Third Amendment Signing Date”), is made among Nabriva Therapeutics Public Limited Company, a public limited company incorporated in Ireland under registration number 599588 and having its registered office at 25-28 N |
|
| March 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 12, 2020 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| March 12, 2020 |
Form of Restricted Share Unit Agreement under the 2017 Share Incentive Plan (Share Withholding) Exhibit 10.10 Form of RSU Award Agreement for Executives (Share Withholding) NABRIVA THERAPEUTICS PLC RESTRICTED SHARE UNIT AGREEMENT GRANTED UNDER 2017 SHARE INCENTIVE PLAN This Restricted Share Unit Agreement (this “Agreement”) is made between Nabriva Therapeutics plc, a public limited company organized under the laws of Ireland (the “Company”), and the Participant pursuant to the 2017 Share Inc |
|
| March 12, 2020 |
Exhibit 10.40 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of January 8, 2020 (the “Amendment Effective Date”), is made among Nabriva Therapeutics Public Limited Company, a public limited company incorporated in Ireland under registration number 599588 and having its registered office at 25-28 North Wall Quay, Dub |
|
| March 12, 2020 |
Subsidiaries of Nabriva Therapeutics plc Exhibit 21.1 SUBSIDIARIES OF NABRIVA THERAPEUTICS plc Nabriva Therapeutics GmbH Austria Nabriva Therapeutics Ireland Designated Activity Company Ireland Zavante Therapeutics, Inc. United States Nabriva Therapeutics US, Inc. United States |
|
| March 12, 2020 |
Description of the Registrant’s Securities Registered under Section 12 of the Exchange Act Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of registered securities of Nabriva Therapeutics plc (“us,” “our,” “we” or the “Company”) is intended as a summary only and therefore is not a complete description. This description is based upon, and is qualified by reference to, our memorandum and articles of association and applicable |
|
| March 12, 2020 |
our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (File No. 001-37558); Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-375 |
|
| February 12, 2020 |
NBRV / Nabriva Therapeutics AG / Longitude Capital Partners II, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nabriva Therapeutics plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) G63637105 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 6, 2020 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| January 8, 2020 |
-PDUFA action date set for June 19, 2020 - Exhibit 99.1 Nabriva Therapeutics Receives FDA Acknowledgement of New Drug Application Resubmission for Intravenous CONTEPO™ (fosfomycin) for Injection -PDUFA action date set for June 19, 2020 - DUBLIN, Ireland, Jan. 8, 2020 - Nabriva Therapeutics plc (NASDAQ: NBRV), a commercial-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infecti |
|
| January 8, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 8, 2020 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commiss |
|
| December 26, 2019 |
NBRV / Nabriva Therapeutics AG / ORBIMED ADVISORS LLC - AMENDMENT NO. 4 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* NABRIVA THERAPEUTICS PLC (Name of Issuer) ORDINARY SHARES (Title of Class of Securities) 62957M104 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP V LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address a |
|
| December 26, 2019 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated December 26, 2019 (the “Schedule 13D”), with respect to the Ordinary Shares, of Nabriva Therapeutics plc is filed, and all amendments thereto will be filed, on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13D. |
|
| December 23, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 20, 2019 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| December 20, 2019 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 20, 2019, between Nabriva Therapeutics plc, an Irish incorporated public limited company (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject t |
|
| December 20, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 20, 2019 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| December 20, 2019 |
Nabriva Therapeutics Announces $20 Million Registered Direct Offering Exhibit 99.1 Nabriva Therapeutics Announces $20 Million Registered Direct Offering DUBLIN, Ireland and KING OF PRUSSIA, Pa., December 20, 2019 — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into a definitive agreement with cer |
|
| December 20, 2019 |
Exhibit 4.1 ORDINARY SHARE PURCHASE WARRANT NABRIVA THERAPEUTICS PLC Warrant Shares: Initial Exercise Date: June , 2020 Issue Date: December , 2019 THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value of $0.0001 received by the Company, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set f |
|
| December 20, 2019 |
Exhibit 99.1 Nabriva Therapeutics Resubmits New Drug Application for Intravenous CONTEPO™ (fosfomycin) for Injection -Nabriva anticipates a six-month review period by the Food and Drug Administration -CONTEPO is a potential first-in-class intravenous antibiotic in U.S. for the treatment of complicated urinary tract infections DUBLIN, Ireland, December 20, 2019 - Nabriva Therapeutics plc (NASDAQ: N |
|
| December 20, 2019 |
13,793,106 Ordinary Shares Warrants to Purchase up to 13,793,106 Ordinary Shares Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No. |
|
| December 20, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 20, 2019 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| December 6, 2019 |
NBRV / Nabriva Therapeutics AG / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* NABRIVA THERAPEUTICS PLC (Name of Issuer) ORDINARY SHARES (Title of Class of Securities) 62957M104 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP V LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address a |
|
| December 6, 2019 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated December 6, 2019 (the “Schedule 13D”), with respect to the Ordinary Shares, of Nabriva Therapeutics plc is filed, and all amendments thereto will be filed, on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13D. |
|
| November 12, 2019 |
NBRV / Nabriva Therapeutics AG 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 12, 2019 |
Exhibit 10.1 Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of September 26, 201 |
|
| November 12, 2019 |
Exhibit 99.1 Nabriva Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights -More than 200 hospital formulary reviews of XENLETATM scheduled before the end of the year- -Approximately 50% of all covered lives have outpatient formulary access to XENLETA- -Initiating focused community sales efforts for XENLETA- -Conference call today at 4:30 p.m. Eastern Time- Dubl |
|
| November 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 12, 2019 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| November 12, 2019 |
Third Quarter 2019 Financial Results & Corporate Update November 12, 2019 Exhibit 99.2 Third Quarter 2019 Financial Results & Corporate Update November 12, 2019 Safe Harbor and Disclaimer This presentation contains forward-looking statements about future expectations, plans and prospects for Nabriva Therapeutics, including but not limited to statements about launch and commercialization of XENLETA for the treatment of CABP, the development of CONTEPO for cUTI, the clini |
|
| September 26, 2019 |
8-K 1 a19-1912418k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 20, 2019 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdict |
|
| September 9, 2019 |
EX-99.2 3 a19-184221ex99d2.htm EX-99.2 Exhibit 99.2 Nabriva Therapeutics Earns $5 Million Milestone Payment under its License Agreement with Sinovant Sciences Dublin, Ireland and King of Prussia, PA., September 6, 2019 — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infectio |
|
| September 9, 2019 |
Exhibit 99.1 Nabriva’s XENLETA™ (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) Now Available in the U.S. First IV and oral antibiotic with novel mechanism of action approved by the FDA in nearly two decades, targets the most common CABP pathogens and supports antibiotic stewardship DUBLIN, Ireland, September 9, 2019 — Nabriva Therapeutics plc (NASDAQ: NBRV), a bioph |
|
| September 9, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 6, 2019 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| August 19, 2019 |
Exhibit 99.2 Nabriva Therapeutics Receives U.S. FDA Approval of Xenleta™ (lefamulin) to Treat Community-Acquired Bacteria Pneumonia (CABP) First New IV and Oral Antibiotic with a Novel Mechanism of Action Approved in Nearly Two Decades Provides Critically Needed Treatment Option for Adult Patients with CABP XENLETA Expected to be Available mid-September 2019 Conference call and webcast today at 4: |
|
| August 19, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 16, 2019 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commiss |
|
| August 19, 2019 |
XenletaTM (lefamulin) FDA Approval Investor Call August 19, 2019 Exhibit 99.1 XenletaTM (lefamulin) FDA Approval Investor Call August 19, 2019 Safe Harbor and Disclaimer This presentation contains forward-looking statements about future expectations, plans and prospects for Nabriva Therapeutics, including but not limited to statements about launch and commercialization of XENLETA for the treatment of CABP, the development of CONTEPO for cUTI, the clinical utili |
|
| August 19, 2019 |
Exhibit 99.3 Nabriva Therapeutics Provides Update on the Planned Resubmission of the New Drug Application for Intravenous CONTEPO™ (fosfomycin) for Injection - NDA resubmission anticipated early in the fourth quarter 2019 – DUBLIN, Ireland, August 16, 2019 — Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the development of innovative anti-infective a |
|
| August 14, 2019 |
NBRV / Nabriva Therapeutics AG / Vivo Capital VIII, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4) * NABRIVA THERAPEUTICS PLC (Name of Issuer) ORDINARY SHARES (Title of Class of Securities) G63637105 (CUSIP Number) August 13, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| August 8, 2019 |
Nabriva Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights Exhibit 99.1 Nabriva Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights Dublin Ireland, August 8, 2019 — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three and six months ended June 30, 2019 and rec |
|
| August 8, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 8, 2019 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| August 8, 2019 |
NBRV / Nabriva Therapeutics AG 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 5, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 31, 2019 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| July 25, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 25, 2019 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| July 1, 2019 |
NBRV / Nabriva Therapeutics AG / Novo A/S - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Nabriva Therapeutics PLC (Name of Issuer) Ordinary Shares, nominal value €0.01 per share (Title of class of securities) 62957M104 (CUSIP number) June 28, 2019 (Date of event which requires filing of this statement) Check the appropriate box to d |
|
| June 25, 2019 |
Up to $50,000,000 Ordinary Shares Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-219567 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED AUGUST 10, 2017) Up to $50,000,000 Ordinary Shares We entered into an Open Market Sale AgreementSM, or the Sale Agreement, with Jefferies LLC, or Jefferies, on June 25, 2019, relating to the sale of our ordinary shares, nominal value $0.01 per share, offered by this p |
|
| June 25, 2019 |
Exhibit 99.1 Nabriva Therapeutics Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application for Lefamulin DUBLIN, Ireland, June 24, 2019 — Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that the European Medicines Agency |
|
| June 25, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 24, 2019 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| June 25, 2019 |
Exhibit 1.1 EXECUTION VERSION OPEN MARKET SALE AGREEMENTSM June 25, 2019 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Nabriva Therapeutics plc, an Irish incorporated public limited company (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “A |
|
| June 20, 2019 |
Financial Statements and Exhibits, Other Events 8-K 1 a19-1179218k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 20, 2019 NABRIVA THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-37558 Not Applicable (State or other jurisdiction o |
